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Abstract 
New approaches to treat ovarian cancer, the fifth leading cause of cancer death among women, 
are being sought, with the targeting of epigenetic modulators now receiving much attention. The 
histone acetyltransferase HBO1 functions in regulating diverse molecular processes, including 
DNA repair, transcription and replication, and is highly expressed in primary ovarian cancer. 
Here we define both the molecular function and a role in cell biomechanics for HBO1 in ovarian 
cancer. HBO1 preferentially acetylates histone H4 through the concomitant overexpression of 
co-regulator JADE2, and is required for the expression of YAP1, an ovarian cancer oncogene 
and mechano-transductor signaling factor. HBO1 appears therefore to have a role in determining 
the mechano-phenotype in ovarian cancer cells, through both signal transduction processes, and 
the modulation of cell elasticity as observed using direct measurements on live cells via Atomic 
Force microscopy. 
 
Keywords 
Acetyltransferase; JADE; YAP1; elasticity; biomechanics 
 
Abbreviations 
OC, ovarian cancer; HAT, histone acetyltransferase; ING, inhibitor of growth; KD, knockdown; 
HGSC, high-grade serous carcinoma; AFM, atomic force microscopy; HOSEpiC, human ovarian 
surface epithelial cells. 
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Introduction 
Alterations in epigenetic regulatory mechanisms play important roles in tumorigenesis and 
changes in histone acetylation/deacetylation have been implicated in a variety of cancers [1]. 
Histone acetyltransferase (HAT) binding to ORC-1 (HBO1, also known as KAT7 and MYST2) 
is a member of the MYST family of HATs [2], nuclear proteins that function within large 
multicomponent protein complexes. The HBO1-complex is recruited by tri-methylated histone 
H3 at lysine (K) 4 and 36, is responsible for H4 acetylation at K5, 8, 12 and 16 [3,4] and also 
mediates H3 acetylation at K14 [5,6]. HBO1 is enriched near transcriptional start sites and within 
gene coding regions [6,7], acts as a specific co-activator for steroid receptors (estrogen receptor 
alpha, progesterone receptor) and other transcription factors [8–10] and represses activities of 
others, including NF-кβ, probably via co-activator sequestration [11,12]. Other components of 
the HBO1-complex include the inhibitor of growth (ING) tumor suppressor proteins 4/5, the Esa-
associated factor 6 (Eaf6) and scaffolding subunits (JADE1/2/3 and BRPF1/2/3) [3,6,7], the 
latter being responsible for directing HBO1-complexes to distinct chromatin regions, defining 
substrate specificity [13,14]. 
 
Several lines of evidence suggest that HBO1 is important in cancers, and it has been found 
overexpressed in ovarian carcinoma, breast adenocarcinoma and testicular germ cell tumors [4]. 
Further, the HBO1 locus (17q21.3) maps to a region that shows frequent allelic gains associated 
with poor prognosis in breast cancers [15,16]. Transient knockdown (KD) of HBO1 potentiates 
anti-estrogen-dependent growth suppression of MCF-7 cells [17] and reduces proliferation in 
several non-breast cell types such as 293T [3] and MLE-12 cells [18]. While these findings 
collectively point to cancer promoting and pro-proliferative activities, HBO1 can also play anti-
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oncogenic roles in other cell types; HBO1 expression is suppressed in acute myeloid leukemia 
and its depletion increases colony formation of THP-1 and SEM leukemic cell lines [19]. 
Further, HBO1-/- mice are non-viable with specific post-gastrulation defects, but cells from pre-
gastrulation HBO1-/- mice proliferate normally [5]. Instead, HBO1-/- embryos display reduced 
expression of genes required for embryonic patterning along with reduced acetylated H3K14, 
with no effects on H4 acetylation. Thus, HBO1 is not always required for cell division and 
influences behavior of different cell types in distinct ways. 
 
Ovarian cancer (OC) is one of the five leading causes of women cancer death worldwide and 
survival rates have improved little in the last 30 years [20,21]. Lethality is due to the 
asymptomatic nature of early disease and lack of long-term effective treatment strategies for 
advanced conditions. There are five distinct major ovarian cancer histo-types (high-grade/low-
grade serous, endometrioid, clear-cell and mucinous), which exhibit distinct clinical features, 
responses to chemotherapy and outcomes [22]. Within these categories, high-grade serous 
carcinoma (HGSC) has the worst prognosis and the highest death rate and represents ~70% of 
epithelial ovarian cancer [22]. HGSC almost always contains mutated TP53 (~95%) and about 
20% of tumors contain germline or somatic mutations in breast cancer susceptibility genes 
(BRCA1/2). Other features are defects in homologous recombination DNA repair pathways 
(50%), CCNE1 amplification and broad genomic instability [23–25]. 
 
Since HBO1 is overexpressed in OC and is frequently associated with enhanced cell division [4], 
we set out to elucidate its functions in OC cells. Reduction of HBO1 expression by synthetic 
knockdown of HBO1 identified a specific role in the acetylation of histone H4, and not H3K14 
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acetylation. Gene expression analysis determined that the mechano-transductor signaling factor 
YAP1 was regulated by HBO1, supporting bioinformatic analysis which suggested that cell 
viability, motility and cytoskeletal reorganization pathways were altered following manipulation 
of HBO1 expression. This prediction was confirmed through analysis of the biomechanical 
properties of OC cells using Atomic Force Microscopy (AFM). The overexpression of HBO1 in 
OC cells resulted in elevated cell elasticity as determined by significantly lower Young’s 
modulus compared to cells subjected to synthetic HBO1 knockdown, and reveals a link between 
epigenetic processes and cell mechanical properties associated with aggressive OC phenotypes. 
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Methods 
 
Cell culture 
The ovarian cancer cell lines used in this study, except COV644 (Sigma
®
; St. Louis, Missouri, 
USA), were purchased from ATCC
®
 (Manassas, Virginia, USA). Human Ovarian Surface 
Epithelial Cells (HOSEpiC) were used as non-cancerous control (ScienceCell™; Carlsbad, 
California, USA). SKOV-3 and OVCAR-3 were maintained in RPMI-1640 (ATCC
®
) 
supplemented with 20% fetal calf serum (FBS, HyClone™; Logan, Utah, USA) and 10 μg/ml of 
insulin solution from bovine pancreas (Sigma
®
). UACC-1598 and UWB1.289 were cultured in 
DMEM/F-12+GlutaMAX™ (Thermo Scientific™, Austin, Texas, USA) (10% FBS), TOV112D 
and TOV21G were maintained in MCDB 105 + M199 (Sigma
®
) (15% FBS) and COV644 in 
DMEM+GlutaMAX™ (Thermo Scientific™) (10% FBS). HOSEpiC cells were cultured in 
Prigrow I (abm
®
; Richmond, Canada) supplemented with 0.01% ovarian epithelial cell growth 
supplement (ScienceCell™) (10% FBS) and grown in extracellular matrix coated-flasks (abm®). 
All cell lines were supplemented with penicillin [100 U/ml] and streptomycin [100 μg/ml] 
(Corning cellgro
®
; Manassas, Virginia, USA) and maintained at 37°C in a humidified 5% CO2 
incubator. All cell lines used in this study were tested and resulted free of mycoplasma 
infections. 
 
Antibodies 
The following commercial antibodies were used for immune blotting with the indicated 
dilutions: anti-HBO1 (1:1000, Abcam
®
; Cambridge, Massachusetts, USA), anti-GAPDH 
(1:2000, Santa Cruz
®
; Dallas, Texas, USA), anti-H4ac (1:1000, Active motif
®
; Carlsbad, 
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California, USA), anti-H4 (1:1000, Active motif
®
), anti-H3K14ac (1:1000, Active motif
®
), anti-
CyPA (1:200, Santa Cruz
®
), anti-XRCC1 (1:250, Santa Cruz
®
) and anti-EGFR (1:250, Santa 
Cruz
®
). Anti-HBO1 (1:100) and Alexa Fluor
®
 488 secondary antibody (1:500, Thermo 
Scientific™) were used for immune-fluorescence staining. 
 
Total RNA extraction and qRT-PCR 
Total RNA was isolated with the RNeasy kit (Qiagen
®
; Germantown, Maryland, USA) and 
reverse transcribed to cDNA using SuperScript
®
 II reverse transcriptase and random primers 
following the first-strand synthesis protocol (Thermo Scientific™). All qRT-PCR reactions were 
conducted in a LightCycler
®
480 II instrument (Roche, Indianapolis, Indiana, USA) using 2X 
SYBR Green I MasterMix. Relative gene expression was determined following the δCt method 
[26] and normalized to GAPDH expression. All samples were tested in duplicates. When 
possible, synthetic oligonucleotides (sequence available upon request) span exon-exon 
boundaries to preclude amplification of genomic DNA. ANOVA statistical analyses were 
performed on δCt values of three biological replicates using Graphpad Prism (V6); the Tukey’s 
HSD test was used to correct for multiple comparison testing. 
 
Protein extraction and western blot 
Cells were lysed using RIPA buffer (150mM NaCl, 50mM Tris pH 7.5, 0.5% sodium 
deoxycholate, 0.1% SDS, 1% Triton X-100, protease inhibitor cocktail [Roche]) and total protein 
was quantified using a standardized bovine serum albumin protein concentration curve following 
the Bio-Rad DC™ protein assay (Bio-Rad; Hercules, California, USA). Total protein samples 
(10μg) were separated using SDS-PAGE and then transferred to a PVDF membrane. Primary 
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antibody incubations were performed overnight (O/N) followed by 2 hours in the presence of 
HRP-conjugated secondary antibodies. Protein intensity was detected with Luminata™ Classico 
HRP substrate (Millipore™; Temecula, California, USA). All western blots were performed 
three times and relative protein intensity levels were calculated using ImageJ [27]. The graphical 
depiction of relative protein levels represents the proportional difference between a treatment and 
its control (100%). ANOVA analyses were performed on relative intensity values using 
Graphpad Prism (V6); the Tukey’s HSD test was used to correct for multiple comparison testing. 
 
Immunofluorescence and subcellular protein fractionation 
Cells were cultured in 4-well chamber slides (Nunc™ Lab-Tek™ II, Thermo Scientific™) and 
grown overnight at 37°C. After this, cells were washed with PBS (HyClone™) twice and fixed 
with 3.7% formaldehyde (Sigma
®
). After several PBS washes, the cells were permeabilized with 
0.25% Triton X-100, blocked for 1h with 3% BSA in PBS and washed thoroughly in PBS again. 
Following this step, cells were incubated with the primary antibody diluted in blocking solution 
for 4h in a dark humidified chamber (4°C) and then with secondary antibody for 1h in the same 
conditions. Slides were mounted with DAPI solution (Thermo Scientific™) as per manufacturer 
instructions and observed in a Nikon Eclipse Ti Microscope (Nikon
®
; Melville, New York, 
USA). Each experiment was repeated twice and one chamber slide containing target cells was 
incubated with the secondary antibody alone as auto-fluorescence control. The subcellular 
protein fractionation was performed three times following manufacturer’s instructions (Thermo 
Scientific™). Cells were cultured in TC dishes (60x15mm, Falcon®; Greenwood, Indiana, USA), 
lysed with RIPA buffer and run in SDS-PAGE gels as indicated in the western blot section. 
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Relative protein intensity, expressed as localization percentage, was calculated using ImageJ 
[27]. 
 
RNA interference 
Cells were cultured O/N in Costar
®
 Clear TC-treated 12-well plates (Sigma
®
) in pertinent media 
without antibiotics. ON-TARGETplus Human KAT7 siRNA-SMART-pool (GE Dharmacon™; 
Lafayette, Colorado, USA) was used in order to transiently knockdown HBO1, while an ON-
TARGETplus Non-targeting pool (GE Dharmacon™) was used as control (siRNA guide 
sequences can be found in the Supplementary Table S1). Cells were transfected with the siRNA 
pool [25nM] or individual siRNAs [6.25nM] using DharmaFECT Transfection Reagent (GE 
Dharmacon™) following manufacturer’s instructions. Cells transfected with Transfection 
Reagent alone were used as non-siRNA control. 
 
Microarray hybridization and analysis 
Human whole genome expression arrays (HumanHT-12 v4) were purchased from Illumina
®
 (San 
Diego, California, USA). Complementary RNA (cRNA) synthesis and labeling were performed 
as described previously [28]. Unmodified microarray data obtained from the GenomeStudio was 
background-subtracted and quantile-normalized using the lumi package [29] within R. To 
determine the effect of RNA interference, microarrays were analyzed using the two-class paired-
rank product method [30,31] within the multiple array viewer (MEV). The analysis was 
corrected for multiple hypotheses testing and the siRNA effect was considered significant when 
the false discovery rate (FDR) fell below the 10% (FDR<0.1). To facilitate comparisons among 
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the datasets, all data was uploaded into an SQLite3 database. The Venn diagram was designed 
using the Venny website (http://bioinfogp.cnb.csic.es/tools/venny/; August 2018). 
 
Pathway analysis 
Ingenuity Pathway Analysis (IPA
®
,
 
Qiagen
®
) was used to compare differentially expressed genes 
with thousands of curated datasets in order to perform functional analysis of the RNA silencing. 
Files containing differentially expressed genes with their associated fold-change values were 
uploaded to IPA
®
. These data was used to determine significantly affected pathways upon 
siRNA depletion (Canonical pathways) and to identify possible influenced downstream 
biological processes. 
 
Determination of viability, cell death and apoptosis 
The ApoTox-Glo™ triplex assay (Promega®, San Luis Obispo, California, USA) allows 
assessing of cell viability, cell death (cytotoxicity) and apoptosis (caspase activity) in the same 
experiment. This assay was performed following manufacturer’s instructions. Substrates were 
always added to un-treated wells and wells without cells as additional controls and all samples 
were tested in triplicates. The graphical depiction of relative cell viability, cytotoxicity and 
caspase activation represents the proportional difference between a treatment and its control 
(100%). ANOVA analyses were performed on raw values using Graphpad Prism (V6); the 
Tukey’s HSD test was used to correct for multiple comparison testing. 
 
Lentiviral infection 
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A set of three SMARTvector™ Lentiviral shRNA KAT7 particles (GE Dharmacon™) was 
purchased in order to constitutively knockdown HBO1. SMARTvector™ Non-targeting 
Lentivirus particles (GE Dharmacon™) were used as negative control (shRNA guide sequences 
can be found in the Supplementary Table S1). The protocol for transduction of lentiviral particles 
was performed following manufacturer’s instructions. Cells were transduced with individual 
shRNAs supplemented with polybrene [10 μg/mL] (Santa Cruz®) for 6h. The transduction 
medium was then replaced by normal growth medium, in which cells proliferated for 2 days. 
Next, cells were cultured for 48h in growth media containing puromycin [1 μg/mL] (Santa 
Cruz
®), a period after which a lower concentration of puromycin [0.5 μg/mL] was added for 
another 48h to reassure the selection of transduced cells. Finally, transduced cells were observed 
in a Nikon Eclipse Ti Microscope (Nikon
®
) to assess green fluorescent protein (GFP) expression. 
 
Atomic Force Microscopy 
Cells were analyzed using a BioScope Catalyst (Bruker Instruments; Santa Barbara, California, 
USA). Novascan borosilicate colloidal probes were used, with a sphere radius of 2.5µm, spring 
constant 0.17 N/m and deflection sensitivity 20.11 nm/V, experimentally determined on a clean 
glass slide. A total of 40 cells per sample type were analyzed. Three force curves were acquired 
on the center of each cell, using a ramp size of 3.5µm, a ramp speed of 1Hz and an applied force 
of 400 pN. The region of contact in each approach curve was fitted with the Hertz model 
(Equation 1, shown below) using the Nanoscope Analysis software (V1.5). 
𝐹 =
4𝐸√𝑅 𝛿3 2⁄
3 (1−𝜐2)
                                               (1) 
In Equation 1, F is the force applied by the cantilever tip to the cell, E is the Young`s modulus 
(fit parameter), υ is the Poisson ratio (0.5), R the radius of the indenter (2.5 µm) and δ the 
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indentation of the cell. Only data displaying a goodness-of-fit higher than 0.9 was taken into 
consideration. Each retraction curve was analyzed for the presence of adhesion events. Data 
distribution and statistical analysis were performed using Wolfram Mathematica 10 and Minitab 
(V17). Mann-Whitney test was used to assess statistical significance between data population. 
 
Accession numbers 
Raw microarray data has been deposited in the Gene Expression Omnibus (GEO) database of the 
NCBI (https://www.ncbi.nlm.nih.gov/gds). GEO accession number GSE89922 corresponds to 
the UWB1.289 microarray and GEO accession number GSE89359 to the OVCAR-3 microarray. 
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Results 
 
HBO1 is highly expressed in ovarian cancer cell lines 
HBO1 expression levels were determined in a panel of OC cell lines (Table 1). HGSC OC cells 
(OVCAR-3, SKOV-3, UWB1.289 and UACC-1598) expressed significantly higher HBO1 
mRNA relative to the non-cancerous ovarian epithelial cell control (HOSEpiC) (Figure 1A). 
Significantly higher expression levels were also detected in the endometrioid line TOV-112D. 
Western blot analysis determined that elevated transcript levels were accompanied by 
concomitant increases in HBO1 protein (Figure 1B). 
 
HBO1 subcellular localization was determined in UWB1.289 using immunofluorescence 
staining, and, as expected, found to be nuclear, evenly distributed throughout the nucleoplasm 
and excluded from the nucleoli (Figure 1C). This distribution was similar, but weaker, in 
HOSEpiC cells (Figure 1C). Subcellular fractionation experiments further confirmed HBO1 was 
predominantly nuclear localized, and that a significant fraction of HBO1 is present in the same 
cellular fraction as chromatin, represented by the histone H4 control (Figure 1D and E). Thus, 
HBO1 is highly expressed in serous OC cell lines versus the non-cancerous control and displays 
normal nuclear localization in this context. 
 
HBO1 is required for histone H4 but not H3K14 acetylation 
To understand the function(s) of HBO1 in OC cells, we performed transient siRNA transfection 
into OVCAR-3 and UWB1.289 cells. Optimal KD was obtained 48 hours after siRNA 
transfection (Supplementary Figure S1), and this treatment led to substantial decreases in steady 
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state HBO1 transcript (70-90%, Figure 2A) and protein (60-80%, Figure 2B and C). 
Furthermore, a stable HBO1 knockdown cell line was generated using lentiviral transduction of 
three different shRNAs in UWB1.289 cells. This approach also rendered a significant stable 
reduction in the expression of HBO1 transcript (50-90%) and protein (40-90%) (Figure 2 D-F). 
Both transient and stable HBO1 KD revealed no obvious changes in cell morphology or 
replication rate when analyzed through the use of light microscopy and raw cell count 
respectively (not shown). 
 
Using the HBO1 KD models we analyzed the levels of acetylation of defined HBO1 histone 
targets, H4 (using a pan-H4 antibody to simultaneously analyze H4K5, 8, 12 and 16) and 
H3K14. Transient HBO1 KD resulted in reduction in bulk H4 acetylation in OVCAR-3 and 
UWB1.289 OC cells (Figure 3A and B), however H3K14 acetylation was unchanged (Figure 3A 
and B), suggesting that HBO1 is primarily involved in H4 acetylation in OC cells, and that 
targeting of H3K14 by HBO1 may be limited to very specific developmental stages and cell 
types, as observed in pre-gastrulation mouse embryos [5,6]. Similarly, stable HBO1 KD also 
resulted in reduced acetylation of histone H4 (Figure 3C and D) and not H3K14 acetylation 
(Figure 3C and D). Together these results suggest that HBO1 has a selective role in maintaining 
H4 acetylation in OC cell lines. 
 
HBO1-complex components are overexpressed in ovarian cancer cell lines 
The specificity observed towards H4 acetylation may be due to the molecular composition and 
therefore selectivity of the HBO1-complex in OC cells, accordingly the relative expression levels 
of HBO1-complex cofactors ING4/5, BRPF1/2/3 and JADE1/2/3 was determined (Figure 4 A-
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C). In OVCAR-3, ING5 expression was approximately 2/3-fold at higher levels than controls 
(Figure 4A). BRPF1 was elevated 1.5/2-fold in both cell lines (Figure 4B). However, JADE2 and 
JADE3 were very highly expressed in OC cells, with exceptionally high levels of JADE2 
transcript present in UWB1.289 cells (~10-fold greater than controls) (Figure 4C). These 
observations suggest that whilst HBO1 could be present in a number of different complexes, it is 
likely that a JADE2/3-associated complex is the most predominant in OC cells. This HBO1-
JADE complex offers an explanation for the histone H4 specificity of HBO1 observed in these 
cells [14]. 
 
HBO1 knockdown results in specific gene expression changes in ovarian cancer cells 
We assessed gene expression changes after transient HBO1 KD in the two OC cell lines via 
microarray. Global transcriptome analyses revealed a number of differentially regulated HBO1-
dependent genes in UWB1.289 (Table 2 and Supplementary Table S2) and OVCAR-3 (Table 2 
and Supplementary Table S3), and were validated by qRT-PCR analysis (Supplementary Figure 
S2). The initial siRNA KD system used in these experiments utilized a pool of four distinct 
siRNA, therefore individual HBO1 siRNAs were also used to validate the observed effect 
(Supplementary Figure S3). Comparative analysis between OVCAR-3 and UWB1.289 gene lists 
identified an ‘HBO1 signature’ gene set (Figure 4D and Table 2), from which selected targets 
were verified by qRT-PCR analysis. CD46, H2AFY and YAP1 genes were significantly down-
regulated, and TSPAN2 was significantly up-regulated in both cell lines (Figure 4E).  
 
HBO1 knockdown increases cell viability in vitro 
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Bioinformatic analysis of HBO1 target gene function predicted an association with enhanced 
cellular movement, migration, invasion and reduced cell death (Supplementary Table S4). 
Whereas measurements for gross cellular activities, including invasion, proliferation and wound-
healing assays did not reveal any functional changes upon HBO1 KD (Supplementary Figure S4 
A-C), increased cell viability was observed (Figure 5A). This effect was accompanied with a 
significant reduction in apoptosis, as determined by measurement of gross caspase activity 
(Figure 5B) and in cell cytotoxicity (Figure 5C). Transient HBO1 KD also resulted in reduced 
levels of CypA/PPIA, a marker of cell death (Figure 5D and E) [32]. Stable knockdown of 
HBO1 using shHBO1 displayed similar increases in viability (Figure 5F). 
 
HBO1 stable knockdown reduces cell membrane elasticity in UWB1.289 cells 
The increased cell viability observed following loss of HBO1, and the lack of effect on general 
processes involved in cancer phenotypes, led us to ask whether HBO1 might be involved in the 
regulation of more subtle oncogenic transformation processes such as cytoskeletal 
reorganization, as has been recently reported for cellular transformation involved in endometrial 
desidualization, a process similar to mesenchymal-to-endothelial transitions (MET) [33]. Atomic 
Force Microscopy (AFM) was used to investigate the surface biomechanical properties in 
UWB1.289 cells (Figure 6A and B). 2.5 µm radius spherical (colloidal) probes, which are suited 
to inspect overall cellular surface changes rather than local nanoscopic differences [34], were 
used to interrogate cell properties including stiffness and adhesiveness. Approach force curves 
were used to extract specific Young’s modulus (Figure 6C and D), and the Hertz equation used 
to fit the contact regime of each approach curve (equation 1 in Methods) and demonstrated an 
excellent goodness of fit (89% > 0.9). 
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A Young’s modulus of 294 ± 14 Pa was measured in cells expressing normal HBO1 levels, 
which increased to 397 ± 17 Pa when HBO1 expression was reduced (Figure 6E), suggesting that 
HBO1 is involved in promoting a less organized/differentiated and more elastic phenotype in OC 
cells, a common characteristic of invasive tumor cells [35]. Consistently, previous AFM data 
demonstrated that the highly metastatic ovarian cancer cell line HEY A8 displayed a Young’s 
modulus of 490 ± 220 Pa, compared to its less aggressive counterpart HEY, where elasticity was 
measured as 880 ± 530 Pa [36]. Surface adhesiveness was evaluated through measuring the force 
needed to detach the spherical probe from the cell surface during a retracting cycle as indicated 
in Figure 6F. In this case, the median adhesion values for the control and transformed cells were 
not significantly different (p > 0.05; 38 ± 2 pN and 39 ± 2 pN). 
 
Cellular elastic properties, known to determine and characterize functional phenotypes in OC 
development, are linked to intrinsic gene regulatory processes including YAP1 pathways [36,37]. 
Overexpression of YAP1, a main downstream nuclear effector of the Hippo signaling pathway, 
has been reported in OC [38,39], where it is thought to act as an oncogene associated with 
aggressive disease and poor prognosis [40,41]. Importantly, YAP1 is also widely regarded as a 
mechano-transducer, as its transcriptional activity is responsive to a complex array of mechanical 
and geometric cues [42]. YAP1 is one of the main target effectors regulated by HBO1, as seen 
previously in OVCAR-3 and UWB1.289 cells (Figure 4E) and other OC cell lines including 
TOV-112D, UACC-1598 and SKOV-3 (Supplementary Figure S5). These results suggest that 
HBO1 influences the mechano-phenotype of OC cells shaping their elasticity, and 
responsiveness to mechanical perturbations via the regulation of YAP1 expression.  
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Discussion 
HGSC is the most common and aggressive OC histo-type and, with the exception of poly (ADP-
ribose) polymerase inhibitors in patients with BRCA1/2 mutations [43], existing therapies 
ultimately yield disappointing results. Identification of target molecules with key roles in HGSC 
phenotype and progression could facilitate the development of new therapies. Since HBO1 is 
overexpressed in serous OC [4], and appears important in cancer proliferation [44], we sought to 
determine the role of HBO1 in OC. 
 
All serous-like OC cell lines evaluated expressed high levels of HBO1 relative to controls, with 
highest levels of HBO1 transcript observed in UACC-1598 and TOV-112D, which were isolated 
from patients with late stages of disease (IV and IIIC respectively). Interestingly, TOV-112D is 
derived from an endometrioid carcinoma that shares similarities with HGSCs [45]. 
 
HBO1 was required for bulk histone H4 acetylation but had no effect on the acetylation status of 
H3K14, suggesting that in OC overexpression of HBO1 may result in a specific acetylation 
function. Loss of HBO1 was not accompanied by any compensatory overexpression of other 
HATs. In fact, PCAF/KAT2B, previously linked to enhanced rates of DNA replication [46], was 
down-regulated when HBO1 was knocked-down. The specificity observed for H4 acetylation is 
likely due to the overexpression of JADE2/3 HBO1 HAT-complex components. The 
composition of the HBO1 complex has been proposed as a mechanism of switching HAT 
activity from one histone target to the other (H3-H4) [14], thus specifically modulating cell 
functionality, and JADE containing HBO1-complexes appear to direct HBO1 activity towards 
histone H4. High levels of JADE2 expression may also have prevented anti-HBO1 antibodies 
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recognizing HBO1 in genome wide chromatin immune-precipitation (ChIP) analysis at due to 
the proposed alteration in the stoichiometry of the HBO1-JADE2 complex. 
 
Transcriptome analysis following depletion of HBO1 in OC cells, in general, pointed to multiple 
oncogenic roles for HBO1. CD46, a complement inhibitor involved in the protection of tumor 
cells against the host immune system, was down-regulated following HBO1 depletion, which is 
consistent with previous studies that reported overexpression in OC tissues, links to shorter 
survival and poor prognosis [47,48]. YAP1, a well-known OC oncogene and mechano-
transducer, was down-regulated in all tested OC cell lines after HBO1 knockdown, suggesting an 
underlying association between epigenome modulation and cell biomechanics [49]. However, 
HBO1 also displayed anti-cancer activities in OC cells, as we observed augmentation of cell 
viability without changes in cell proliferation following HBO1 knockdown. While it may be 
surprising that overexpression of HBO1 is associated with anti-oncogenic activities, there are 
precedents for this phenomenon in other cancer cell types, e.g. the transcription factor NR2F2 is 
overexpressed in breast cancer, yet NR2F2 knockdown in MDAMB231 and MCF-7 breast 
cancer cells led to enhanced migration and invasion without changes in proliferation [50]. 
 
Recent studies have revealed four strong gene expression subtypes in HGSC, termed 
immunoreactive, differentiated, proliferative and mesenchymal [25]. While these subgroups were 
not associated with obvious changes in overall survival, their existence may indicate that 
different approaches are needed to combat individual OC subtypes. Our genome wide pathway 
analysis data revealed that loss of HBO1 function overlaps with the OC mesenchymal signature, 
including increased cell survival, migration, cytoskeletal organization and microtubule dynamics. 
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It is therefore interesting to consider the possibility that HBO1 overexpression suppresses the 
mesenchymal phenotype to favor others. 
 
Whilst reduction in HBO1 expression did not appear to have any significant effect on 
proliferation, migration or invasion in OC cells, a significant decrease in cell elasticity, which is 
commonly associated with aggressive cancer phenotypes, was observed [51]. Differences in cell 
elasticity have been reported between non-malignant and ovarian cancer cells using AFM, where 
higher levels of membrane elasticity have been correlated to both high migratory and invasive 
activity [36]. The cell cytoskeleton has a central role in cell structure and intracellular 
organization, and thus affects cell mechanical properties that ultimately dictate cell functionality 
[51]. Interestingly, as cells transform from non-malignant to cancerous states, their cytoskeletal 
structure changes from an organized to an irregular network, reducing cell stiffness thus 
stimulating a more ‘elastic’ phenotype. Accordingly, cancer cells are softer and more 
deformable, which eventually leads to increased ability to infiltrate tissues and spread [52]. 
Reduction of HBO1 expression resulted in a significant decrease in cell membrane elasticity, a 
feature that is consistent with an aggressive cancer phenotype [51]. Direct comparison of the 
measured Young’s modulus for UWB1.289 (this study) and the highly invasive HEY A8 cells 
[36], suggests that UWB1.289 could be a more aggressive ovarian cancer cell type as it has 
higher membrane elasticity. These findings, together with the identification of a mechano-
transducer as a major HBO1 target, suggest that this HAT regulates different molecular 
mechanisms that effectively influence OC biomechanics. 
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Figure legends 
 
Figure 1. HBO1 is overexpressed in ovarian cancer cell lines 
Cell lysates from 7 ovarian cancer cell lines and a non-cancerous control (HOSEpiC) were 
subjected to (A) qRT-PCR and (B) western blot analyses. All values represent the mean ± SD of 
at least three biological samples (*p<0.05; ***p<0.001; ****p<0.0001). (C) Immune-
fluorescence staining showing HBO1 localization in HOSEpiC and UWB1.289 cells. First 
column (Bright-field) displays optical microscopic images of cells; second (DAPI) and third 
(Alexa Fluor
®
 488) show fluorescent-labeled DNA and HBO1 images respectively. Scales 
represent 10μm. (D) Subcellular protein fractionation of UWB1.289 cell lysates shows a nuclear 
distribution of HBO1 (~83% NF + ChF). CF: cytoplasm fraction, MF: membrane fraction, NF: 
nuclear fraction, ChF: chromatin fraction. EGFR, XRCC1 and Histone 4 antibodies were used as 
positive controls. (E) Pie chart showing the cellular distribution of HBO1 protein according to 
the subcellular protein fractionation. Immune-fluorescence and subcellular fractionation 
experiments were performed twice. 
 
Figure 2. HBO1 knockdown resulted in significant mRNA and protein depletion 
SiRNA-mediated knockdown in OVCAR-3 and UWB1.289 cells resulted in significant HBO1 
(A) transcript and (B) protein reduction after 48 hours compared to the control treatment (siCtrl). 
(C) Proportional difference between relative densities of HBO1 protein in knockdown and 
control samples; relative densities were calculated using ImageJ. The transduction of three 
shRNAs (1-3) in UWB1.289 cells led to significant HBO1 (D) transcript and (E) protein 
reduction compared to the non-targeting control (shCtrl). (F) Proportional difference between 
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relative densities of HBO1 protein in knockdown and control samples; relative densities were 
calculated using ImageJ. All values represent the mean ± SD of three biological samples 
(*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001). 
 
Figure 3. HBO1 directs histone H4 acetylation in ovarian cancer cells 
(A) HBO1 knockdown reduced bulk histone H4 acetylation in OVCAR-3 and UWB1.289 cells 
compared to the control treatment (siCtrl), however H3K14 acetylation remained unchanged 
after 48h. (B) Proportional differences of acetylated H4 and acetylated H3K14 compared to the 
histone 4 controls after transient HBO1 knockdown. (C) Stable knockdown of HBO1 using three 
shRNAs (1-3) reduced bulk histone H4 acetylation when compared to the non-targeting control 
(shCtrl), while no effect was observed in H3K14 acetylation. (D) Proportional differences of 
acetylated H4 and acetylated H3K14 compared to the histone 4 controls after stable HBO1 
knockdown. All values represent the mean ± SD of three biological samples (*p<0.05; **p< 
0.01). 
 
Figure 4. Expression levels of the HBO1-complex regulate important subsets of genes in 
ovarian cancer cell lines 
(A) Inhibitor of growth (ING) tumor suppressor proteins 4/5 mRNA expression level in 
OVCAR-3 and UWB1.289 cells compared to the non-cancerous control (HOSEpiC). (B) 
Scaffolding subunits BRPF1/2/3 mRNA expression level comparison. (C) Scaffolding subunits 
JADE1/2/3 mRNA expression level comparison. (D) Venny depiction of HBO1-regulated genes 
in OVCAR-3 and UWB1.289 cell lines following transient depletion of HBO1 (48h). (E) qRT-
PCR validation of HBO1-associated genes in HBO1 knockdown lysates of OVCAR-3 and 
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UWB1.289 cells. All values represent the mean ± SD of three biological samples (*p<0.05, 
**p<0.01; ***p<0.001, ****p<0.0001).  
 
Figure 5. HBO1 regulates cell viability and apoptosis in vitro 
After HBO1 knockdown, OVCAR-3 and UWB1.289 cells were subjected to (A) Viability, (B) 
Apoptosis (caspase activation) and (C) Cytotoxicity assays. The graphical representations 
display the proportional difference between HBO1 knockdown and control measurements 
(siCtrl). Each HBO1 knockdown was compared to their correspondent cell line control sample 
but only one control was plotted in order to simplify the images. (D) siRNA-mediated HBO1 
knockdown led to a significant reduction in CypA/PPIA protein levels in UWB1.289 after 48h. 
(E) Proportional difference between relative densities of CypA/PPIA protein in knockdown and 
control samples; relative densities were calculated using ImageJ. (F) UWB1.289 cells expressing 
shHBO1 1 and the non-targeting control (shCtrl) were subjected to viability, caspase activity and 
cytotoxicity assays. The graphical representation displays the proportional difference between 
HBO1 knockdown and control measurements. The value of each assay was compared to its 
correspondent control but only one was plotted in order to simplify the image. All values 
represent the mean ± SD of three biological samples (*p<0.05). 
 
Figure 6. Stable HBO1 knockdown significantly increases the Young modulus of 
UWB1.289 cell membrane 
UWB1.289 cells transduced with lentiviral constructions targeting (A) HBO1 and (B) non-
targeting control (shCtrl) displayed normal morphology and expressed high levels of green 
fluorescent protein (GFP) linked to shRNA production. Examples of (C) approach and (D) 
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retract Atomic Force Microscopy (AFM) curves applied onto UWB1.289 cells. (E) Stable 
knockdown of HBO1 (shHBO1 1) led to a significant increase in membrane tension compared to 
the control: 397±17 Pa and 294±14 Pa, respectively (*p<0.05). (F) Surface adhesiveness for 
shHBO1 1, 39±2 pN, was not significantly different from shCtrl, 38±2 pN (n.s: not significant). 
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Table 1. Ovarian cancer and non-cancerous cell lines used in the study 
Cell line Histology Grade Stage 
HOSEpiC Ovarian surface epithelium   
SKOV-3 Serous - - 
OVCAR-3 High-grade serous 3 - 
UWB1.289 Serous - - 
UACC-1598 Serous 3 IV 
TOV-112D Endometrioid 3 IIIC 
TOV-21G Clear-cell 3 III 
COV644 Mucinous - - 
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Table 2. Common gene expression changes caused by HBO1 knockdown in OVCAR-3 and 
UWB1.289 cell lines 
Gene 
Fold-change 
OVCAR-3 
Fold-change 
UWB1.289 
OAS2 4.15 1.75 
IFIT1 3.25 1.64 
CXCL10 3.18 1.55 
IFIT2 2.54 1.52 
OASL 2.02 1.53 
MX1 1.76 1.50 
IRF9 1.74 1.52 
GBP5 1.60 2.04 
TSPAN2 1.59 1.50 
GBP1 1.58 1.81 
RASSF2 1.52 1.88 
TLE4 1.51 1.50 
MAP2 1.50 2.35 
CDR2 -1.50 -1.95 
RNF141 -1.50 -1.52 
AGFG1 -1.52 -1.51 
MYST2 -1.54 -2.70 
RABL2A -1.55 -2.09 
H2AFY -1.55 -2.13 
TNFRSF10D -1.55 -2.00 
S100A2 -1.56 -1.74 
CHORDC1 -1.57 -2.60 
CD46 -1.62 -1.81 
RABL2B -1.64 -2.04 
C3orf64 -1.73 -1.83 
SMPDL3B -1.79 -1.63 
ADRB2 -1.96 -1.87 
LOC648927 -2.09 -4.01 
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Graphical abstract 
 
The histone acetyltransferase HBO1 is overexpressed in ovarian cancer cell lines and exerts 
specific epigenetic regulation through the assembly and targeting of multi-protein complexes, 
which include JADE scaffolding subunits. This study showed that HBO1 preferentially targets 
histone H4 for acetylation, and has a significant involvement in the regulation of mechano-
transduction pathways and cell elasticity in ovarian cancer cells. 
ACCEPTED MANUSCRIPT
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
